The World Health Organization (WHO) has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. So far at least one person has died after contracting the virus, in a lab-confirmed case. This is the first time in a while that the virus has resurfaced, and a few of the Ebola-related stocks are responding.
In the last major outbreak between 2014 and 2015, over 11,000 people died in West Africa, mainly in Guinea, Sierra Leone and Liberia.
24/7 Wall St. has taken a quick look at a few stocks that have an Ebola treatment in their portfolio or deal directly with the virus. We have included a recent trading history, as well as some color and the consensus analyst price target.
Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares up 1.5% at $34.02, with a consensus analyst price target of $60.88 and a 52-week trading range of $14.83 to $63.73. Year to date, shares are up 22%.
Lakeland Industries Inc. (NASDAQ: LAKE) shares are up over 8% at $11.94. The stock has a 52-week range of $8.00 to $11.95 and a consensus price target of $15.00. So far in 2017, excluding Friday’s move, the stock is up nearly 6%.
Novavax Inc. (NASDAQ: NVAX) shares are up 1% at $0.94, with a consensus price target of $3.48 and a 52-week range of $0.73 to $8.49. Year to date, the stock is down 26%.
NewLink Genetics Corp. (NASDAQ: NLNK) saw its stock jump 3.6% to $17.45, within a 52-week range of $9.41 to $25.17 and with a consensus price target of $26.80. In 2017, the stock is up 63%.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares are up nearly 1% at $90.16. The stock has a 52-week range of $73.45 to $102.49. Year to date, the stock is up about 8%.